Seeking Computational & Organoid Partners to De-Risk Nanofiber-Based GBM R&D

About Migration Biotherapeutics

Migration Biotherapeutics is a UK-based biotechnology start-up dedicated to transforming the management of invasive glioblastoma multiforme (GBM). Our core innovation, the ALIGHT device, is a non-pharmacological "ecological trap" designed to exploit the natural migratory instincts of cancer cells. By utilising electrospun PCL nanofibers that mimic the brain's white matter tracts, the device redirects invasive cells away from healthy tissue and into a retention matrix for localised management.

Technical Context & Innovation

The ALIGHT device utilises contact guidance and topographical cues to manage tumour recurrence. This physical approach offers a simplified surgical profile and avoids the systemic toxicity and blood-brain barrier challenges associated with traditional pharmacological interventions.

Collaboration Goals for Cluster Health 2026

We are actively seeking to join or form consortia for the Horizon Europe Cluster Health 2026 calls, with a primary focus on Destination 5 (New Approach Methodologies) and Destination 6 (Regulatory Science). We are specifically looking for high-level research organisations with expertise in:

• In Silico Computational Modelling: To develop predictive "Digital Twin" models of our device’s cell-steering mechanisms, providing the necessary data to de-risk our R&D and clinical translation.

• 3D Cancer Organoid Models: To validate the device's efficacy within high-fidelity, patient-derived tumour microenvironments, establishing preclinical proof-of-concept.

• Advanced Bio-fabrication: Groups with specialised expertise in medical-grade electrospinning and the development of innovative biomaterial scaffolds for neurological applications.

Why Partner with Us?

Migration Biotherapeutics offers a mature, industrial-grade platform technology with a clear commercialization roadmap. We provide a unique opportunity for academic partners to apply advanced NAMs (New Approach Methodologies) to a tangible, high-impact medical device that addresses a critical unmet need in oncology. We bring the agility of a startup and a collaborative R&D culture.